StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Jul 2026 09:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Form DEF 14A Co-Diagnostics, Inc. For: Jul 21 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+21/26793248.html si-local-file:///var/storage/secattach/20260721/26793248.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+21/26793248.html Tue, 21 Jul 2026 09:00:00 -0400 CODX O.29488102 Form DEF 14A Co-Diagnostics, Inc. For: Jul 21 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+21/26793248.html si-local-file:///var/storage/secattach/20260721/26793248.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+21/26793248.html Tue, 21 Jul 2026 09:00:00 -0400 CODX O.29488102 Co-Diagnostics names Wes Lindsey as chief scientific officer http://www.streetinsider.com/Corporate+News/Co-Diagnostics+names+Wes+Lindsey+as+chief+scientific+officer/26777474.html <p>Co-Diagnostics, Inc. (Nasdaq: CODX) has appointed Wes Lindsey, PhD, MBA as its new Chief Scientific Officer, the Salt Lake City-based molecular diagnostics company announced.</p><p>Dr. Lindsey holds a PhD in Genetics and Molecular Biology from Emory University and an MBA from Georgia State University. He brings more than 20 years of experience in molecular diagnostics, including leading assay development and R&D teams that produced more than a dozen FDA 510(k) submissions and CE-marked assays for in vitro diagnostic products.</p><p>"Wes brings two decades of experience building and leading molecular diagnostics teams through FDA clearance, including point-of-care and near-point-of-care IVDs, and that expertise http://www.streetinsider.com/Corporate+News/Co-Diagnostics+names+Wes+Lindsey+as+chief+scientific+officer/26777474.html Thu, 16 Jul 2026 09:01:10 -0400 CODX Co-Diagnostics names Wes Lindsey as chief scientific officer http://www.streetinsider.com/Management+Changes/Co-Diagnostics+names+Wes+Lindsey+as+chief+scientific+officer/26777474.html <p>Co-Diagnostics, Inc. (Nasdaq: CODX) has appointed Wes Lindsey, PhD, MBA as its new Chief Scientific Officer, the Salt Lake City-based molecular diagnostics company announced.</p><p>Dr. Lindsey holds a PhD in Genetics and Molecular Biology from Emory University and an MBA from Georgia State University. He brings more than 20 years of experience in molecular diagnostics, including leading assay development and R&D teams that produced more than a dozen FDA 510(k) submissions and CE-marked assays for in vitro diagnostic products.</p><p>"Wes brings two decades of experience building and leading molecular diagnostics teams through FDA clearance, including point-of-care and near-point-of-care IVDs, and that expertise http://www.streetinsider.com/Management+Changes/Co-Diagnostics+names+Wes+Lindsey+as+chief+scientific+officer/26777474.html Thu, 16 Jul 2026 09:01:10 -0400 CODX Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733034-1&h=3913365370&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733034-1&h=3913365370&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733034-1&h=3913365370&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733034-1&h=3913365370&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733034-1&h=3913365370&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733034-1&h=3913365370&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733034-1&h=3913365370&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733034-1&h=3913365370&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733034-1&h=3913365370&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733034-1&h=3913365370&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733034-1&h=3913365370&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733034-1&h=3913365370&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 Form PRE 14A Co-Diagnostics, Inc. For: Jul 09 http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+09/26754721.html si-local-file:///var/storage/secattach/20260710/26754721.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+09/26754721.html Fri, 10 Jul 2026 06:01:00 -0400 CODX O.29488102 Form PRE 14A Co-Diagnostics, Inc. For: Jul 09 http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+09/26754721.html si-local-file:///var/storage/secattach/20260710/26754721.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+09/26754721.html Fri, 10 Jul 2026 06:01:00 -0400 CODX O.29488102 Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Invited+to+Participate+in+NPOC+Tuberculosis+Diagnostics+Workshop+in+Bangkok%2C+Thailand/26745229.html <div class="xn-content"> <p class="prntac"><i>Invited by the <span>Stop TB Partnership</span> and the <span>Global Fund</span> to participate as a manufacturer partner</i></p><p class="prntac"><i>Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of <span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>-recommended near-point-of-care diagnostics</i></p><p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4727344-1&h=2151999176&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate as a manufacturer partner in the <span value="ACORN:5020183502" http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Invited+to+Participate+in+NPOC+Tuberculosis+Diagnostics+Workshop+in+Bangkok%2C+Thailand/26745229.html Wed, 08 Jul 2026 09:00:00 -0400 A.02927364 A.17568957 A.50201835 A.60012006 CODX O.03285274 O.04889877 O.22417402 O.29488102 O.60179957 Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Invited+to+Participate+in+NPOC+Tuberculosis+Diagnostics+Workshop+in+Bangkok%2C+Thailand/26745229.html <div class="xn-content"> <p class="prntac"><i>Invited by the <span>Stop TB Partnership</span> and the <span>Global Fund</span> to participate as a manufacturer partner</i></p><p class="prntac"><i>Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of <span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>-recommended near-point-of-care diagnostics</i></p><p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4727344-1&h=2151999176&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate as a manufacturer partner in the <span value="ACORN:5020183502" http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Invited+to+Participate+in+NPOC+Tuberculosis+Diagnostics+Workshop+in+Bangkok%2C+Thailand/26745229.html Wed, 08 Jul 2026 09:00:00 -0400 A.02927364 A.17568957 A.50201835 A.60012006 CODX O.03285274 O.04889877 O.22417402 O.29488102 O.60179957 Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Invited+to+Participate+in+NPOC+Tuberculosis+Diagnostics+Workshop+in+Bangkok%2C+Thailand/26745229.html <div class="xn-content"> <p class="prntac"><i>Invited by the <span>Stop TB Partnership</span> and the <span>Global Fund</span> to participate as a manufacturer partner</i></p><p class="prntac"><i>Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of <span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>-recommended near-point-of-care diagnostics</i></p><p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4727344-1&h=2151999176&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate as a manufacturer partner in the <span value="ACORN:5020183502" http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Invited+to+Participate+in+NPOC+Tuberculosis+Diagnostics+Workshop+in+Bangkok%2C+Thailand/26745229.html Wed, 08 Jul 2026 09:00:00 -0400 A.02927364 A.17568957 A.50201835 A.60012006 CODX O.03285274 O.04889877 O.22417402 O.29488102 O.60179957 Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Invited+to+Participate+in+NPOC+Tuberculosis+Diagnostics+Workshop+in+Bangkok%2C+Thailand/26745229.html <div class="xn-content"> <p class="prntac"><i>Invited by the <span>Stop TB Partnership</span> and the <span>Global Fund</span> to participate as a manufacturer partner</i></p><p class="prntac"><i>Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of <span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>-recommended near-point-of-care diagnostics</i></p><p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4727344-1&h=2151999176&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate as a manufacturer partner in the <span value="ACORN:5020183502" http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Invited+to+Participate+in+NPOC+Tuberculosis+Diagnostics+Workshop+in+Bangkok%2C+Thailand/26745229.html Wed, 08 Jul 2026 09:00:00 -0400 A.02927364 A.17568957 A.50201835 A.60012006 CODX O.03285274 O.04889877 O.22417402 O.29488102 O.60179957 Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Invited+to+Participate+in+NPOC+Tuberculosis+Diagnostics+Workshop+in+Bangkok%2C+Thailand/26745229.html <div class="xn-content"> <p class="prntac"><i>Invited by the <span>Stop TB Partnership</span> and the <span>Global Fund</span> to participate as a manufacturer partner</i></p><p class="prntac"><i>Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of <span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>-recommended near-point-of-care diagnostics</i></p><p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4727344-1&h=2151999176&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate as a manufacturer partner in the <span value="ACORN:5020183502" http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Invited+to+Participate+in+NPOC+Tuberculosis+Diagnostics+Workshop+in+Bangkok%2C+Thailand/26745229.html Wed, 08 Jul 2026 09:00:00 -0400 A.02927364 A.17568957 A.50201835 A.60012006 CODX O.03285274 O.04889877 O.22417402 O.29488102 O.60179957 Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Invited+to+Participate+in+NPOC+Tuberculosis+Diagnostics+Workshop+in+Bangkok%2C+Thailand/26745229.html <div class="xn-content"> <p class="prntac"><i>Invited by the <span>Stop TB Partnership</span> and the <span>Global Fund</span> to participate as a manufacturer partner</i></p><p class="prntac"><i>Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of <span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>-recommended near-point-of-care diagnostics</i></p><p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4727344-1&h=2151999176&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate as a manufacturer partner in the <span value="ACORN:5020183502" http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Invited+to+Participate+in+NPOC+Tuberculosis+Diagnostics+Workshop+in+Bangkok%2C+Thailand/26745229.html Wed, 08 Jul 2026 09:00:00 -0400 A.02927364 A.17568957 A.50201835 A.60012006 CODX O.03285274 O.04889877 O.22417402 O.29488102 O.60179957 Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Invited+to+Participate+in+NPOC+Tuberculosis+Diagnostics+Workshop+in+Bangkok%2C+Thailand/26745229.html <div class="xn-content"> <p class="prntac"><i>Invited by the <span>Stop TB Partnership</span> and the <span>Global Fund</span> to participate as a manufacturer partner</i></p><p class="prntac"><i>Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of <span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>-recommended near-point-of-care diagnostics</i></p><p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4727344-1&h=2151999176&u=https%3A%2F%2Fco-dx.com%2F&a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate as a manufacturer partner in the <span value="ACORN:5020183502" http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Invited+to+Participate+in+NPOC+Tuberculosis+Diagnostics+Workshop+in+Bangkok%2C+Thailand/26745229.html Wed, 08 Jul 2026 09:00:00 -0400 A.02927364 A.17568957 A.50201835 A.60012006 CODX O.03285274 O.04889877 O.22417402 O.29488102 O.60179957